10 Largest Biotech Hedge Funds and Their Top Stock Picks
The ability to successfully make money through investment requires deep thinking and analysis.
Apellis Pharmaceuticals Inc. (APLS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | EcoR1 Capital Oleg Nodelman | 11,607,425 | $445,260,823 | +3% | 13.62% |
| 2. | VenBio Select Advisor Kurt Von Emster | 11,111,111 | $426,222,218 | 5.67% | |
| 3. | Octagon Capital Advisors Ting Jia | 2,880,880 | $110,510,557 | +3% | 17.36% |
| 4. | Deep Track Capital David Kroin | 2,500,000 | $95,900,000 | +150% | 2.86% |
| 5. | 2,000,000 | $76,720,000 | 6.17% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $40.00 | 250,000 | Large Shareholder | 12,806,342 | 2021-11-18 | Filing | |
| $31.81 | 5,000 | Director | 5,000 | 2020-05-08 | Filing | |
| $37.00 | 540,540 | Large Shareholder | 12,556,342 | 2020-01-13 | Filing | |
| $29.71 | 11,699 | Officer | 11,699 | 2019-08-29 | Filing | |
| $17.00 | 441,176 | Large Shareholder | 12,015,802 | 2019-03-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $36.79 | 7,524 | 100,000 | 2024-09-16 | Filing | ||
| $36.09 | 29,476 | 107,524 | 2024-09-16 | Filing | ||
| $36.21 | 192 | Officer | 38,141 | 2024-09-16 | Filing | |
| $39.49 | 550 | Officer | 38,333 | 2024-09-03 | Filing | |
| $39.63 | 1,695 | 136,998 | 2024-06-21 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,445,290 | $984,415,060 | 0.18% | |
| 2. | 9,555,678 | $572,002,885 | 0.01% | |
| 3. | 5,381,253 | $322,121,807 | 0% | |
| 4. | 3,275,922 | $196,096,693 | 0.14% | |
| 5. | 3,097,141 | $185,394,859 | 0.01% |
News See All
10 Best Mid-Cap Healthcare Stocks To Buy Now
According to projections by ReportLinker, the market for healthcare services will increase from $7.5 trillion in 2022 to $7.975 trillion in 2023.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q2 2024 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the Apellis Pharmaceuticals Second Quarter 2024 Earnings Conference Call.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2024 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. reports earnings inline with expectations. Reported EPS is $-0.54 EPS, expectations were $-0.54. Apellis Pharmaceuticals, Inc.
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2023 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.73 EPS, expectations were $-0.66. Apellis Pharmaceuticals, Inc.
Wall Street Analysts Just Trimmed Price Targets for These 5 Stocks
In this article, we discuss the 5 stocks receiving price-target cut from analysts.
5 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds
Below we present the list of 5 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q3 2023 Earnings Call Transcript
Operator: Good morning ladies and gentlemen. Thank you for standing by and welcome to the Apellis Pharmaceuticals Third Quarter 2023 Earnings Conference Call.
Wall Street Analysts See Upside Potential for 5 Stocks with Rising Price Targets
In this article, we discuss the 5 stocks receiving price-target hike from Wall Street analysts.
Billionaire Hedge Funds
